Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STALORAL Birch 300 IR in children with birch pollen allergy
NCT05668390Phase 3Completed
- Sponsor
- Stallergenes Greer
- Start
- Sep 2023
- Primary completion
- Aug 2025
- Modality
- Allergy Immunotherapy
- Countries
- 12
01
Overview
A Phase 3 trial of allergenic extract of birch in allergic rhinoconjunctivitis (ARC), sponsored by Stallergenes Greer. Started Sep 2023; status: completed.
02
Drugs
allergenic extract of birch
03
Conditions
allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on NCT05668390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05668390.